Purpose: Compassion is integral to nursing, yet the concept of compassionate care is not thoroughly understood. This study aimed to clarify the nature of compassionate care among Korean clinical nurses using a hybrid model. Methods: This study utilized a mixed methods approach involving hybrid concept analysis to explore the nature and attributes of compassionate care, encompassing both theoretical and empirical stages. In the theoretical stage, the domains, attributes, and a preliminary definition of compassionate care were formulated. In the fieldwork stage, in-depth interviews with 18 nurses were conducted to gather insights, which were integrated in the final stage. Results: Compassionate care was categorized into three domains: cognitive, relational, and behavioral, with 11 defining attributes. It was defined as the capacity to recognize individual patient needs, engage empathetically with their suffering, establish trust through emotional connection, and deliver therapeutic partnership, specialized, personalized, ethical, and holistic care. Conclusion This study advances the understanding of compassionate care in nursing by providing a multidimensional framework. It lays the groundwork for future research and practical applications, emphasizing the need for measurement tools and strategies to promote compassionate care among clinical nurses.

Purpose: Compassion is integral to nursing, yet the concept of compassionate care is not thoroughly understood. This study aimed to clarify the nature of compassionate care among Korean clinical nurses using a hybrid model. Methods: This study utilized a mixed methods approach involving hybrid concept analysis to explore the nature and attributes of compassionate care, encompassing both theoretical and empirical stages. In the theoretical stage, the domains, attributes, and a preliminary definition of compassionate care were formulated. In the fieldwork stage, in-depth interviews with 18 nurses were conducted to gather insights, which were integrated in the final stage. Results: Compassionate care was categorized into three domains: cognitive, relational, and behavioral, with 11 defining attributes. It was defined as the capacity to recognize individual patient needs, engage empathetically with their suffering, establish trust through emotional connection, and deliver therapeutic partnership, specialized, personalized, ethical, and holistic care. Conclusion This study advances the understanding of compassionate care in nursing by providing a multidimensional framework. It lays the groundwork for future research and practical applications, emphasizing the need for measurement tools and strategies to promote compassionate care among clinical nurses.

Purpose: Compassion is integral to nursing, yet the concept of compassionate care is not thoroughly understood. This study aimed to clarify the nature of compassionate care among Korean clinical nurses using a hybrid model. Methods: This study utilized a mixed methods approach involving hybrid concept analysis to explore the nature and attributes of compassionate care, encompassing both theoretical and empirical stages. In the theoretical stage, the domains, attributes, and a preliminary definition of compassionate care were formulated. In the fieldwork stage, in-depth interviews with 18 nurses were conducted to gather insights, which were integrated in the final stage. Results: Compassionate care was categorized into three domains: cognitive, relational, and behavioral, with 11 defining attributes. It was defined as the capacity to recognize individual patient needs, engage empathetically with their suffering, establish trust through emotional connection, and deliver therapeutic partnership, specialized, personalized, ethical, and holistic care. Conclusion This study advances the understanding of compassionate care in nursing by providing a multidimensional framework. It lays the groundwork for future research and practical applications, emphasizing the need for measurement tools and strategies to promote compassionate care among clinical nurses.

The concept of e-sports is being established as a sport that we have previously recognized, not just a simple electronic game. However, it is not clear whether e-sports share the same characteristics as sports, and even if they do, how doping will be a problem in e-sports. In this paper, we examined how to deal with the doping issue in e-sports by comparing the characteristics of general sports and e-sports. We also investigated what form doping will take in e-sports and what information pharmacists should know in the future. In conclusion, it is necessary to expand the scope of anti-doping activities that have been actively implemented in existingsports to the field of e-sports to prevent damage to the health of e-sports athletes and maintain fairness and transparency in e-sportsactivities. In addition, it is thought that pharmacists, who are experts in medication, will need to understand the overall characteristicsof e-sports and the differences in the target group at risk of doping and activate their role in providing individualized pharmaceuticalservices in the future.

The concept of e-sports is being established as a sport that we have previously recognized, not just a simple electronic game. However, it is not clear whether e-sports share the same characteristics as sports, and even if they do, how doping will be a problem in e-sports. In this paper, we examined how to deal with the doping issue in e-sports by comparing the characteristics of general sports and e-sports. We also investigated what form doping will take in e-sports and what information pharmacists should know in the future. In conclusion, it is necessary to expand the scope of anti-doping activities that have been actively implemented in existingsports to the field of e-sports to prevent damage to the health of e-sports athletes and maintain fairness and transparency in e-sportsactivities. In addition, it is thought that pharmacists, who are experts in medication, will need to understand the overall characteristicsof e-sports and the differences in the target group at risk of doping and activate their role in providing individualized pharmaceuticalservices in the future.

The concept of e-sports is being established as a sport that we have previously recognized, not just a simple electronic game. However, it is not clear whether e-sports share the same characteristics as sports, and even if they do, how doping will be a problem in e-sports. In this paper, we examined how to deal with the doping issue in e-sports by comparing the characteristics of general sports and e-sports. We also investigated what form doping will take in e-sports and what information pharmacists should know in the future. In conclusion, it is necessary to expand the scope of anti-doping activities that have been actively implemented in existingsports to the field of e-sports to prevent damage to the health of e-sports athletes and maintain fairness and transparency in e-sportsactivities. In addition, it is thought that pharmacists, who are experts in medication, will need to understand the overall characteristicsof e-sports and the differences in the target group at risk of doping and activate their role in providing individualized pharmaceuticalservices in the future.

The concept of e-sports is being established as a sport that we have previously recognized, not just a simple electronic game. However, it is not clear whether e-sports share the same characteristics as sports, and even if they do, how doping will be a problem in e-sports. In this paper, we examined how to deal with the doping issue in e-sports by comparing the characteristics of general sports and e-sports. We also investigated what form doping will take in e-sports and what information pharmacists should know in the future. In conclusion, it is necessary to expand the scope of anti-doping activities that have been actively implemented in existingsports to the field of e-sports to prevent damage to the health of e-sports athletes and maintain fairness and transparency in e-sportsactivities. In addition, it is thought that pharmacists, who are experts in medication, will need to understand the overall characteristicsof e-sports and the differences in the target group at risk of doping and activate their role in providing individualized pharmaceuticalservices in the future.

Background: s/Aims: Reported incidence of extrahepatic bile duct cancer is higher in Asians than in Western populations. Korea, in particular, is one of the countries with the highest incidence rates of extrahepatic bile duct cancer in the world. Although research and innovative therapeutic modalities for extrahepatic bile duct cancer are emerging, clinical guidelines are currently unavailable in Korea. The Korean Society of Hepato-Biliary-Pancreatic Surgery in collaboration with related societies (Korean Pancreatic and Biliary Surgery Society, Korean Society of Abdominal Radiology, Korean Society of Medical Oncology, Korean Society of Radiation Oncology, Korean Society of Pathologists, and Korean Society of Nuclear Medicine) decided to establish clinical guideline for extrahepatic bile duct cancer in June 2021. Methods: Contents of the guidelines were developed through subgroup meetings for each key question and a preliminary draft was finalized through a Clinical Guidelines Committee workshop. Results: In November 2021, the finalized draft was presented for public scrutiny during a formal hearing. Conclusions The extrahepatic guideline committee believed that this guideline could be helpful in the treatment of patients.

Background/Aims: Potassium channel tetramerization domain containing 17 (KCTD17) protein, an adaptor for the cullin3 (Cul3) ubiquitin ligase complex, has been implicated in various human diseases; however, its role in hepatocellular carcinoma (HCC) remains elusive. Here, we aimed to elucidate the clinical features of KCTD17, and investigate the mechanisms by which KCTD17 affects HCC progression. Methods: We analyzed transcriptomic data from patients with HCC. Hepatocyte-specific KCTD17 deficient mice were treated with diethylnitrosamine (DEN) to assess its effect on HCC progression. Additionally, we tested KCTD17-directed antisense oligonucleotides for their therapeutic potential in vivo. Results: Our investigation revealed the upregulation of KCTD17 expression in both tumors from patients with HCC and mouse models of HCC, in comparison to non-tumor controls. We identified the leucine zipper-like transcriptional regulator 1 (Lztr1) protein, a previously identified Ras destabilizer, as a substrate for KCTD17-Cul3 complex. KCTD17-mediated Lztr1 degradation led to Ras stabilization, resulting in increased proliferation, migration, and wound healing in liver cancer cells. Hepatocyte-specific KCTD17 deficient mice or liver cancer xenograft models were less susceptible to carcinogenesis or tumor growth. Similarly, treatment with KCTD17-directed antisense oligonucleotides (ASO) in a mouse model of HCC markedly lowered tumor volume as well as Ras protein levels, compared to those in control ASO-treated mice. Conclusions KCTD17 induces the stabilization of Ras and downstream signaling pathways and HCC progression and may represent a novel therapeutic target for HCC.

Background: This study assessed the efficacy and safety of triple therapy with pioglitazone 15 mg add-on versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and dapagliflozin. Methods: In this multicenter, double-blind, randomized, phase 3 study, patients with T2DM with an inadequate response to treatment with metformin (≥1,000 mg/day) plus dapagliflozin (10 mg/day) were randomized to receive additional pioglitazone 15 mg/day (n=125) or placebo (n=125) for 24 weeks. The primary endpoint was the change in glycosylated hemoglobin (HbA1c) levels from baseline to week 24 (ClinicalTrials.gov identifier: NCT05101135). Results: At week 24, the adjusted mean change from baseline in HbA1c level compared with placebo was significantly greater with pioglitazone treatment (–0.47%; 95% confidence interval, –0.61 to –0.33; P<0.0001). A greater proportion of patients achieved HbA1c <7% or <6.5% at week 24 with pioglitazone compared to placebo as add-on to 10 mg dapagliflozin and metformin (56.8% vs. 28% for HbA1c <7%, and 23.2% vs. 9.6% for HbA1c <6.5%; P<0.0001 for all). The addition of pioglitazone also significantly improved triglyceride, highdensity lipoprotein cholesterol levels, and homeostatic model assessment of insulin resistance levels, while placebo did not. The incidence of treatment-emergent adverse events was similar between the groups, and the incidence of fluid retention-related side effects by pioglitazone was low (1.5%). Conclusion Triple therapy with the addition of 15 mg/day of pioglitazone to dapagliflozin plus metformin was well tolerated and produced significant improvements in HbA1c in patients with T2DM inadequately controlled with dapagliflozin plus metformin.